Skip to main content
. 2018 Jan 29;7(5):e1423184. doi: 10.1080/2162402X.2017.1423184

Figure 8.

Figure 8.

CD161-expressing CD4+ and CD8+ T cell phenotypes in NSCLC tumors. (A-B) Histograms represent the percentages of cells producing Granzyme B (GzB), IFN-γ or TFN-α among PMA/Ionomycin-stimulated CD161− or CD161+ CD4+ T cells (A), and CD161− or CD161+ CD8+ T cells (B) in NSCLC tumors, n = 18. (C-D) Upper heat maps illustrate the percentages of cells producing Granzyme B (GzB), IFN-γ or TFN-α among PMA/Ionomycin-stimulated CD4+ CD161− T cells and CD4+ CD161+ T cells (A) or CD8+ CD161− T cells and CD8+ CD161+ T cells (B) in NSCLC tumors, n = 18. Lower heat maps illustrate the percentages of cells expressing CD38 (n = 14), CD69 (n = 11), CD96 (n = 9), CD30L (n = 9), CD40L (n = 11), OX40 (n = 11), 4-1BB (n = 11), CD27 (n = 13), PD-1 (n = 15), Tim-3 (n = 13) or CD103 (n = 12) among CD4+ CD161− T cells and CD4+ CD161+ T cells (A), or CD8+ CD161− T cells and CD8+ CD161+ T cells (B) in NSCLC tumors. P values were calculated using Wilcoxon (paired, non-gaussian) test between CD161− and CD161+ cells. *p<0.05, **p<0.005, ***p<0.001.